Insider Selling: BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Sells $920,400.00 in Stock
Insider Selling: BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Sells $920,400.00 in Stock
BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) CEO Neil Kumar sold 120,000 shares of the stock in a transaction that occurred on Thursday, January 5th. The shares were sold at an average price of $7.67, for a total value of $920,400.00. Following the completion of the sale, the chief executive officer now directly owns 1,492,722 shares of the company's stock, valued at approximately $11,449,177.74. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
BridgeBio Pharma,Inc.(納斯達克評級代碼:BBIO-GET)首席執行官尼爾·庫馬爾在1月5日星期四的一筆交易中出售了120,000股該公司股票。這些股票的平均價格為7.67美元,總價值為920,400.00美元。出售完成後,首席執行官現在直接擁有1,492,722股公司股票,價值約11,449,177.74美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可在此超鏈接.
Neil Kumar also recently made the following trade(s):
尼爾·庫馬爾最近還進行了以下交易:
- On Thursday, November 17th, Neil Kumar sold 34,640 shares of BridgeBio Pharma stock. The shares were sold at an average price of $9.40, for a total value of $325,616.00.
- 11月17日,星期四,尼爾·庫馬爾出售了34,640股BridgeBio Pharma的股票。這些股票的平均價格為9.40美元,總價值為325,616.00美元。
BridgeBio Pharma Price Performance
BridgeBio Pharma價格表現
Shares of BridgeBio Pharma stock opened at $7.39 on Monday. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of -2.20 and a beta of 0.62. The business has a fifty day simple moving average of $8.91 and a two-hundred day simple moving average of $9.84. BridgeBio Pharma, Inc. has a 1 year low of $4.98 and a 1 year high of $15.40.
BridgeBio Pharma的股票週一開盤報7.39美元。該公司市值為11.億美元,市盈率為-2.20倍,貝塔係數為0.62。該業務的50日簡單移動均線切入位為8.91美元,200日簡單移動均線切入位為9.84美元。BridgeBio Pharma,Inc.的一年低點為4.98美元,一年高位為15.40美元。
Analyst Ratings Changes
分析師評級發生變化
Separately, JPMorgan Chase & Co. cut their price target on BridgeBio Pharma from $20.00 to $19.00 and set an "overweight" rating for the company in a report on Friday, November 18th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $23.00.
另外,摩根大通在11月18日星期五的一份報告中將BridgeBio Pharma的目標價從20.00美元下調至19.00美元,並將該公司的評級定為“增持”。根據MarketBeat.com的數據,五位研究分析師對該股的評級為買入,目前該股的平均評級為“買入”,平均目標價為23.00美元。
Institutional Inflows and Outflows
機構資金流入和流出
Several large investors have recently added to or reduced their stakes in the company. Kore Private Wealth LLC increased its position in BridgeBio Pharma by 2.6% during the 3rd quarter. Kore Private Wealth LLC now owns 39,243 shares of the company's stock worth $390,000 after buying an additional 1,000 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in BridgeBio Pharma by 6.9% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 24,878 shares of the company's stock valued at $247,000 after purchasing an additional 1,613 shares in the last quarter. Martingale Asset Management L P raised its stake in BridgeBio Pharma by 4.3% in the third quarter. Martingale Asset Management L P now owns 41,375 shares of the company's stock valued at $412,000 after purchasing an additional 1,694 shares in the last quarter. Arizona State Retirement System raised its stake in BridgeBio Pharma by 13.1% in the second quarter. Arizona State Retirement System now owns 18,001 shares of the company's stock valued at $163,000 after purchasing an additional 2,086 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in BridgeBio Pharma by 16.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 14,589 shares of the company's stock valued at $145,000 after purchasing an additional 2,091 shares in the last quarter. Institutional investors own 96.46% of the company's stock.
幾家大型投資者最近增持或減持了該公司的股份。Kore Private Wealth LLC在第三季度將其在BridgeBio Pharma的頭寸增加了2.6%。Kore Private Wealth LLC在此期間又購買了1,000股,現在擁有39,243股該公司股票,價值39萬美元。三菱UFJ國賽資產管理公司第三季增持BridgeBio Pharma股份6.9%。三菱UFJ國賽資產管理有限公司在上個季度增持了1,613股後,現在持有24,878股該公司股票,價值24.7萬美元。Martingale Asset Management L P在第三季度將其在BridgeBio Pharma的持股增加了4.3%。Martingale Asset Management L P在上個季度額外購買了1,694股後,現在擁有41,375股該公司股票,價值412,000美元。亞利桑那州退休系統在第二季度將其在BridgeBio Pharma的持股增加了13.1%。亞利桑那州退休系統現在擁有18,001股該公司的股票,價值16.3萬美元,上個季度又購買了2,086股。最後,AllSpring Global Investments Holdings LLC在第三季度將其在BridgeBio Pharma的持股比例提高了16.7%。AllSpring Global Investments Holdings LLC現在擁有14,589股該公司股票,價值145,000美元,上個季度又購買了2,091股。機構投資者持有該公司96.46%的股票。
BridgeBio Pharma Company Profile
BridgeBio製藥公司簡介
(Get Rating)
(獲取評級)
BridgeBio Pharma, Inc engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
BridgeBio Pharma,Inc.致力於發現、開發和交付各種治療遺傳病的藥物。該公司有一個30個開發項目的流水線,其中包括從早期發現到後期開發的候選產品。其正在開發的產品包括AG10和BBP-265,這是一種轉甲狀腺素的小分子穩定劑,或TTR,正處於治療TTR澱粉樣變性-心肌病(ATTR-CM)的第三階段臨牀試驗;BBP-831,一種小分子選擇性FGFR1-3抑制劑,這是治療兒科患者軟骨發育不全的第二階段臨牀試驗;以及BBP-631,一種AAV5基因轉移候選產品,正處於第二階段臨牀試驗,用於治療由21-羥基酶缺乏(21OHD)驅動的先天性腎上腺增生症(CAH)。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on BridgeBio Pharma (BBIO)
- Is Goldman Sachs as Good as Gold in Your Portfolio?
- Will LI Auto Be the Least Hated Chinese EV Stock in 2023?
- Here's Why Snap Stock Can Double in 2023
- Which Streaming Service Stock is Best in 2023?
- MarketBeat: Week in Review 01/02-01/06
- 免費獲取StockNews.com關於BridgeBio Pharma的研究報告(BBIO)
- 在你的投資組合中,高盛和黃金一樣好嗎?
- 理想汽車會成為2023年最不招人恨的中國電動汽車股嗎?
- 以下是Snap股票在2023年翻一番的原因
- 哪種流媒體服務股票是2023年最好的?
- MarketBeat:回顧中的一週01/02-01/06
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
獲得BridgeBio Pharma Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收BridgeBio Pharma和相關公司的最新新聞和分析師評級的每日摘要。